Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003814 · ClinicalTrials.gov registry record · Phase 3
Eflornithine in Treating Patients With Bladder Cancer
A Phase 3 study of Bladder Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT00003814: Completed Phase 3 study of Bladder Cancer, sponsored by National Cancer Institute (NCI).
NCT00003814 is a Phase 3 study of Bladder Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 450 participants, below the 12,751-participant average among 175 other Bladder Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003814, a Phase 3 study of Bladder Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if eflornithine is more effective than no further therapy in treating bladder cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of eflornithine in treating patients who have newly diagnosed or recurrent bladder cancer.
Conditions Studied
Interventions
- DRUG eflornithine
Study Locations (20)
California
- Advanced Urology Medical Center - Anaheim
- Citrus Valley Urological Medical Group - Glendora
- University of California San Diego Cancer Center - La Jolla
- San Diego Urology Center - La Mesa
- South Coast Urological Medical Group - Laguna Hills
- Foothill Urology Associates - Pasadena
- San Bernadino Urological Associates - San Bernadino
- DRC and Urological Physicians of San Diego - San Diego
- UCSF Cancer Center and Cancer Research Institute - San Francisco
Florida
- Tampa Bay Meical Research - Clearwater
- University of Florida - Gainesville - Gainesville
- Urology Health Center - New Port Richey
- Barzell, Whitmore, Treiman and Dunne - The Urology Treatment Center - Sarasota
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Alabama
- Urology Associates - Birmingham
- Intouch Research - Huntsville
Georgia
- Piedmont Urology PC - Atlanta
- Georgia Urology - Atlanta
Connecticut
- Urology Specialists, P.C. - Waterbury
District of Columbia
- George Washington University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 1999-02 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
What the finished NCT00003814 record still lists
NCT00003814 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 12,751-participant average among 175 other Bladder Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which eflornithine is the first listed.
NCT00003814 names 20 study sites across 6 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00003814 about?
NCT00003814 is a clinical study titled "Eflornithine in Treating Patients With Bladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if eflornithine is more effective than no further therapy in treating bladder cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of efl...
What is the current status of trial NCT00003814?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 1999-02. Estimated completion is 2007-05.
What conditions does trial NCT00003814 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT00003814?
The interventions under investigation include: eflornithine (DRUG).
Who is sponsoring clinical trial NCT00003814?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003814 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003814's enrollment target sits among peer trials
450 36th of 175 higher than 139 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
RECRUITING · Phase 3
-
A Study of Surgical Techniques During Cystectomy
RECRUITING · Phase 3
-
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
RECRUITING · Phase 3
-
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia